Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd. announced it will present at the Jefferies Healthcare Conference in New York City on June 4, 2026. CEO Ivor Elrifi and COO/CFO Keeren Shah will deliver a corporate presentation, highlighting the company's recent clinical and corporate updates. The company expressed enthusiasm for sharing its progress and strategic direction with the investment community.

Tiziana Life Sciences Ltd announced the completion of patient enrollment in its Phase 2a clinical trial evaluating intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This randomized, double-blind, placebo-controlled study, known as INFORM-MS, enrolled 48 patients across multiple U.S. sites. The company anticipates releasing topline data in late Q3 2026, with further presentation scheduled for the ACTRIMS and ECTRIMS meeting in October 2026.

Tiziana Life Sciences has completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2a clinical trial (INFORM-MS) for intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This multicenter study enrolled 48 patients across U.S. sites, marking the first placebo-controlled Phase 2 trial for the novel anti-CD3 monoclonal antibody. Topline data is anticipated in late Q3 2026 and will be presented at the ACTRIMS and ECTRIMS meeting in October 2026. Following the blinded phase, all participants will have the option to enter a six-month open-label extension to assess long-term safety and sustained benefits.

Tiziana Life Sciences announced new positive clinical data from its ongoing Expanded Access Program for intranasal foralumab in 14 patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). The updated data, covering March 2025 to March 2026, showed that foralumab was extremely well tolerated over extended treatment durations. Patients exhibited encouraging trends in disability stabilization as measured by EDSS and meaningful improvements in fatigue, with 64% achieving a clinically significant improvement in MFIS scores. While the small sample size means the data is not statistically significant, it supports further investigation into foralumab as a potential treatment.

Tiziana Life Sciences announced initial quantitative PET imaging results from the first two Multiple System Atrophy (MSA) patients in its Phase 2 clinical trial for intranasal foralumab. The results showed a marked reduction in brain inflammation, with up to approximately 35% reduction in standardized uptake value (SUV) and 24% reduction in standardized uptake value ratio (SUVR) in affected brain regions. This marks the third indication where intranasal foralumab has demonstrated reduced inflammation on PET scans, highlighting its potential for neurodegenerative conditions like MSA, which currently lacks approved disease-modifying treatments.

Tiziana Life Sciences announced positive preclinical data for its intranasal foralumab in a Long COVID mouse model. The study, published in bioRxiv, showed that nasal anti-CD3 treatment significantly reduced neuroinflammation, boosted regulatory T cells in the brain, restored hippocampal neurogenesis, and improved short-term memory. These findings suggest a promising, non-invasive strategy to address cognitive impairment in Long COVID patients and support the broad therapeutic potential of foralumab.

Tiziana Life Sciences announced that a late-breaking poster on its Phase 2a study of intranasal foralumab in Multiple System Atrophy (MSA) has been accepted for presentation at the 7th World Parkinson Congress. The poster will detail the design and rationale of the TILS-025 trial, which is the first clinical investigation of intranasal anti-CD3 therapy in MSA. This presentation highlights the company's progress in developing a potential treatment for a rapidly progressive neurodegenerative disorder with high unmet medical need.